Daniel P. Petrylak

TL;DR: The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.

TL;DR: The purpose of determining the number of patients whose PSA level drops in a phase II trial of AIPC is to guide the selection of agents for further testing and phase III trials and developed practical guidelines for using PSA as a measurement of outcome.

TL;DR: The enhanced expression of PSMA in tissues and LNCaP cells after androgen deprivation suggests that PSMA is upregulated in the majority of prostate carcinomas after androgens treatment, and suggests thatPSMA may be a clinically useful target for antibody-and genetic-directed therapy of prostate cancer that recurs after androd deprivation.

TL;DR: This work identified a subpopulation of cells that survive Docetaxel exposure that lacks differentiation markers and HLA class I (HLAI) antigens, while overexpressing the Notch and Hedgehog signaling pathways, and exhibited potent tumor-initiating capacity, establishing a link between chemotherapy resistance and tumor progression.

TL;DR: The results suggest that tumors exhibiting decreased expression of the RB gene-coded product (Rb protein) had a more aggressive biological behavior than those that expressed the Rb protein in the majority of their tumor cells.